LOS ANGELES, August 26, 2022 - Indi Molecular today announced that it has been granted U.S. Patent 11,414,460 entitled “KRAS-Specific Cyclic Peptides, Compositions, and Methods of Using and Making” along with Institute for Systems Biology.
Read MoreThe company retains two powerful, advanced PCC molecules targeting ovarian and pancreatic cancer, respectively.
Read MoreWe can build molecules that are small, able to carry a payload and that are highly specific in their binding ability.
Read MoreIndi Molecular’s CEO and co-founder, Albert A. Luderer, Ph.D., will present at the Anglonordic Life Science Conference held virtually May 25 - 28, 2021.
Read MoreIndi Molecular’s CEO and co-founder, Albert A. Luderer, Ph.D., will present at the Spring 2021 Oncology Investor Conference on March 31. A video of his presentation is available...
Read MoreIndi Molecular’s CEO and co-founder, Albert A. Luderer, Ph.D., will present at Biocom’s 11th Annual Global Life Science Partnering Conference held virtually February 23-25, 2021. His presentation will be available on-demand to conference participants.
Read MoreIndi Molecular’s CEO and co-founder, Albert A. Luderer, Ph.D., will present at BIO’s 2021 CEO & Investor Digital Conference held virtually February 16-18, 2021.
Read MoreCULVER CITY, CA, March 3, 2020 - Indi Molecular today announced that Chemical Science has published an article on a combined computational and synthetic approach for developing antibiotics against drug resistant pathogens called antibody-recruiting protein-catalyzed capture agents (AR-PCCs).
Read MoreIndi Molecular’s Vice President R&D Operations, Heather Agnew, Ph.D., will speak at the Boulder Peptide Symposium on September 24, 2019, at the St. Julien Hotel, Boulder, CO. The presentation time is September 24 at 9:15 AM (Peptide Showcase).
Read MoreChalfont St Giles, UK & Culver City, CA, May 14 2019 - GE Healthcare and Indi Molecular, Inc, a California-based biotechnology company, have announced plans to develop immune cell-targeted Positron-Emission Tomography (PET) tracer candidates, based on Indi Molecular’s proprietary Protein Catalyzed Capture (PCC) technology.
Read MoreIndi Molecular’s CEO and co-founder, Albert A. Luderer, Ph.D., will present at the 16th Annual Anglonordic Life Science Conference in London on Wednesday May 8th.
Read MoreIndi Molecular’s Vice President R&D Operations, Dr. Heather Agnew, will speak at TIDES: Oligonucleotide and Peptide Therapeutics on May 22, 2019, at the Manchester Grand Hyatt, San Diego, CA.
Read MoreCULVER CITY, CA, March 8, 2019 - Chemical Reviews has published a major review of protein-catalyzed capture agent (PCC) technology.
Read MoreIndi Molecular’s CEO, Dr. Albert A. Luderer will speak at Biotech Showcase on January 9, 2019 at the Hilton Union Square, San Francisco, CA. The presentation time is January 9 10:30 AM and it will be held in Franciscan D (Ballroom Level).
Read MoreCULVER CITY, CA – August 31, 2018 – Indi Molecular, an emerging life sciences company, announced today that it has appointed Joey Mason, M.D., as Board Member.
Read MoreCULVER CITY, CA – August 22, 2018 – Indi Molecular, an emerging life sciences company, announced today that it has appointed Michael T. Klimas Ph.D. as senior vice president of strategy and technical business development.
Read MoreCulver City, CA, August 3, 2018 - Indi Molecular, an emerging biotechnology company, today announced it has published preclinical data in Analytical Chemistry demonstrating the development of a barcoded rapid assay platform for the analysis of hits from PCC macrocyclic peptide library screens.
Read MoreCULVER CITY, CA – April 26, 2018 – Indi Molecular today announced it has appointed Junfeng “Jafar” Wang to its Board of Directors.
Read More